Luca Filippi,Cristina Ferrari,Giuseppe Rubini
Luca Filippi
Introduction: Sarcomas encompass a highly diverse range of malignancies, characterized by varied morphological and molecular profiles. Treatment options in case of therapy-refractory or advanced disease are limited. In th...
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia [0.03%]
评估靶向ApoC3的siRNA疗法plozasiran治疗重度高甘油三酯血症的临床潜力
Xuan L Tang,Amanda J Hooper,John R Burnett
Xuan L Tang
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma [0.03%]
复发/转移性鼻咽癌治疗的系统性药物临床研发进展
Kelvin Yan,Darren Wt Lim,Brigette B B Y Ma
Kelvin Yan
Introduction: Nasopharyngeal carcinoma (NPC) remains an endemic disease in certain parts of the world, with many patients presenting with advanced disease on diagnosis. Chemotherapy had remained the standard of care with ...
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease [0.03%]
MASLD和MASH的命名变更会对肝病治疗策略产生影响吗？
Kelly Dale,Yasmeen Fallouh,Naim Alkhouri
Kelly Dale
Ralph A Tripp,David E Martin
Ralph A Tripp
Introduction: Respiratory viruses are responsible for significant worldwide morbidity and mortality. While vaccines are highly effective at reducing the morbidity and mortality associated with viral infections, this prote...
Shyam Sundar,Vishal Kumar Singh,Neha Agrawal et al.
Shyam Sundar et al.
Introduction: Over the past 20 years, significant progress has been made in anti-leishmanial therapy. Three new drugs/formulations are available for the treatment of various forms of leishmaniasis, namely oral miltefosine...
Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease [0.03%]
工程化抗体（单链可变片段和纳米体）在靶向阿尔茨海默病病理蛋白聚集体中的应用
Yuan Zhang,Wanpeng Yu,Lei Zhang et al.
Yuan Zhang et al.
Introduction: The misfolding and aggregation of proteins are associated with various neurodegenerative diseases, such as Alzheimer's disease (AD). The small-molecule engineered antibodies, such as single-chain fragment va...
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial [0.03%]
一项针对东亚成人的单次剂量Rilipropartil单克隆抗体（人源化抗C1s）I期、开放标签随机试验的药代动力学、药效学、安全性和耐受性结果
Yingxin Li,Joo Young Na,Yunting Zhu et al.
Yingxin Li et al.
Objectives: This Phase 1 trial was planned to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single dose of riliprubart in healthy East-Asian adult participants. ...
The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects [0.03%]
SHR-2004在健康受试者中的I期临床研究：中国首个FXI单克隆抗体首次人体试验，评估药物的安全性、耐受性、药代动力学和药效学特征
Tingting Ma,Zuyi Weng,Bei Cao et al.
Tingting Ma et al.
Background: Inhibiting the coagulation factor XI (FXI) is a novel strategy for prevention and treatment of thromboembolism without affecting extrinsic coagulation pathways. SHR-2004 is a humanized monoclonal antibody that...
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid receptor antagonist, in healthy men [0.03%]
HRS-1780（一种选择性非甾体类盐皮质激素受体拮抗剂）在健康男性中I期四项一体首次人体研究，以评估其安全性、耐受性、药代动力学、药效学以及浓度-QTc关系
Qi Shen,Lingzhi Li,Weilin Qian et al.
Qi Shen et al.
Background: This first-in-human study evaluated HRS-1780, an oral selective non-steroidal mineralocorticoid receptor antagonist, in healthy men. Research ...